Eli Lilly acquires Ventyx Biosciences, a smaller drugmaker, for $1.2 billion in cash, gaining access to a promising pipeline candidate, VTX3232, which has produced encouraging mid-stage results in obese patients with cardiovascular risk factors. The acquisition highlights Eli Lilly’s strategy to expand its pipeline beyond weight management drugs, with recent acquisitions such as SiteOne Therapeutics and Verve Therapeutics. While Eli Lilly’s current weight management drugs remain key growth drivers, the company is preparing for future challenges and opportunities in areas like oncology. The acquisition news boosted Eli Lilly’s shares, showcasing investor confidence in the company’s strategic moves.

Read more at Yahoo Finance: Could Acquiring Ventyx Biosciences Send Eli Lilly Stock Soaring in 2026?